AGAlain Goudeau

Alain Goudeau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alain Goudeau has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand

    by Woottichai Khamduang, Catherine Gaudy-Graffin, Nicole Ngo-Giang-Huong, Gonzague Jourdain, Alain Moreau, Nuananong Luekamlung, Guttiga Halue, Yuwadee Buranawanitchakorn, Sura Kunkongkapan, Sudanee Buranabanjasatean, et al.

    Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known. HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030) and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg). At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log10 IU/mL and 4.47 log10 copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24%) lost HBsAg and 7 of 8 (88%) HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months). HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L. All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients in resource-limited countries where the vast majority of co-infected patients are currently receiving 3TC.


  • Open Access

    Mutations within the Hepatitis C Virus Genotype 1b E2-PePHD Domain Do Not Correlate with Treatment Outcome

    by Catherine Gaudy, Marie Lambelé, Alain Moreau, Pascal Veillon, Francoise Lunel, Alain Goudeau

    The hepatitis C virus (HCV) envelope protein 2 (E2) interacts in vitro with the interferon alpha (IFN-α)-inducible double-stranded RNA-activated protein kinase, suggesting a possible mechanism by which HCV may evade the antiviral effects of IFN-α. Variability in the part of the HCV E2 gene encoding the carboxy-terminal part of the protein, which includes the interaction domain (E2-PePHD), was explored in 25 patients infected with HCV genotype 1b and receiving IFN-α therapy. PCR products were generated and sequenced for 15 patients with a sustained response and for 10 patients with no virological response after treatment with IFN-α and ribavirin. PePHD amino acid sequences were obtained for isolates from serum collected before and during treatment, after 2 months in responders, and after 6 months in nonresponders. Quasispecies analysis of the pretreatment PePHD region was performed for isolates from patients displaying amino acid substitutions in this domain on direct sequencing. The E2-PePHD sequence was highly conserved in both resistant and susceptible genotype 1b strains and was identical to the prototype HCV type J sequence. No significant emergence of PePHD mutants during therapy was observed in our clonal analysis, and sporadic mutations and treatment outcomes were not found to be correlated. The PePHD sequence before or during treatment cannot be used to predict reliably the outcome of treatment in HCV type 1b-infected patients.


  • Open Access

    Significance of Pretreatment Analysis of Hepatitis C Virus Genotype 1b Hypervariable Region 1 Sequences To Predict Antiviral Outcome

    by Catherine Gaudy, Alain Moreau, Pascal Veillon, Stephanie Temoin, Francoise Lunel, Alain Goudeau

    The heterogeneity of hypervariable region 1 (HVR1), located at the amino terminus of the E2 envelope, may be involved in resistance to alpha interferon (IFN-α) treatment. We investigated whether peculiar HVR1 domain profiles before treatment were associated with the maintenance of sensitivity or the appearance of resistance to treatment. Fifteen patients infected with hepatitis C virus genotype 1b and treated with IFN with or without ribavirin were selected. Ten responded to treatment (groups R1 and R2) and five did not (group NR). The amino acid sequences of 150 naturally occurring HVR1 variants present in the serum before therapy were compared in relation to treatment outcome. HVR1 variants from the NR group contained a constant nonantigenic amino acid segment that was not found in HVR1 variants from the R groups.


    • 15 May 2000
      • Vol. 50  (10) , 1071-7

    [Diagnosis and biological surveillance of hepatitis C virus infections].

    by A Goudeau, F Dubois

    HCV-specific laboratory assays are broadly used to establish the diagnosis, to survey viral replication and to monitor anti-viral treatments. Third-generation ELISA's have an excellent sensitivity well adapted to the early diagnosis. Positive or dubious screening tests must be controlled on a second blood sample. We recommend the use of an immunoblot assay for this control. Regular survey of the immunoblot profile may facilitate the identification of recent infections and help distinguish between active or resolutive infections. PCR assays which detect HCV ARN in serum are very usefull to decide and monitor anti-viral treatments. Their cut-off is usually in the range of 100 genomes/mL. Quantitative assays to measure viral load may also rely on PCR technology or be based on the so-called "branched DNA" technology slightly less sensitive. Genotyping or serotyping of HCV is crucial to adapt specific treatment protocols to the less responsive genotypes 1a et 1b. Cloning and sequencing of HCV isolates is necessary to explore nosocomial clusters of infections or intra-familial cases.

    • 26 October 1999
      • Vol. 23, 985-6

    [Transmission by colonoscopy of hepatitis C virus: apropos of a group of 97 patients at "presumed risk"].

    by D Karsenti, E H Metman, J Viguier, P Blanc, S Doumerc, F Dubois, A Goudeau


    • 1 October 1998
      • Vol. 56  (4) , 417-26

    [Anti-HCV serology for screening, diagnosis and surveillance of hepatitis C: role of the immunoblot].

    by F Dubois, F Barin, A Goudeau

    Screening for antibody to hepatitis C virus (anti-HCV) is usually carried out using microplate enzyme immunoassays (EIA). According to French Ministry of Health recommendations, any positive or dubious result has to be controlled on a second blood sample with a anti-HCV assay differing from the one used for the initial screening. This second test can either be another EIA or an immunoblot assay. The present article investigates the advantage of a strip immunoblot assay including 4-viral peptides (Riba-3) for this control. The use of Riba for the early diagnosis of hepatitis C infection and for the follow-up of infected patients is also evaluated. Riba can be used to assess false positive EIA reactions, for instance in cases with isolated antibody to NS5. From large clinical series, it appears that positive Riba serum profiles can be divided in two main groups: Strongly positive sera associate at least strong (3 or 4+) anti-capsid and anti-NS3 antibody reactivities. These profiles are often completed by anti-NS4 and/or anti-NS5 reactivities. Such profiles are associated with HCV viremia in about 90% of the cases. In this group, prevalence of viremia reaches 100% in patients with elevated level of serum alanin aminotransferase (ALT) and is slightly less frequent, 85%, in patients with normal level of ALT; Weakly positive sera lack either anti-capsid or anti-NS3 antibodies or exhibit only low reactivities (1+ or 2+) to these two antigens. These profiles can also be associated with antibodies to NS4 and/or NS5. Only 10% of patients with such Riba profiles are viremic. Weakly positive profile can be encountered during the early phase of HCV infection (recent seroconversion) or in patients who experience a favourable evolution of their HCV infection. Change of Riba profiles during follow-up provides fruitful information on recent seroconversions (increase in number and intensity of the reactivities). It can also help predict the outcome of HCV infection, a diminution of the intensity of Riba reactivities will confirm the extinction of viral replication.


  • Hepatitis C in a Hemodialysis Unit: Molecular Evidence for Nosocomial Transmission

    by S. Le Pogam, D. Le Chapois, R. Christen, F. Dubois, F. Barin, A. Goudeau

    This study reports four cases of transmission of the rare hepatitis C virus genotype 4 which occurred in a hemodialysis unit and originated from a single source of infection. Phylogenetic analyses performed with the NS5b domain showed that all four patients with secondary infections were infected with virus strains very similar to that of the index patient. Cross infections probably resulted from breaches in safety precautions and lack of dialysis machine sterilization.


    • 1 January 1997
      • Vol. 21, S25-32

    [Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection].

    by J C Desenclos, F Dubois, N Mariotte, A Goudeau


    • 7 September 1996
      • Vol. 25  (25) , 1169

    [Detection of hepatitis B: better efficacy at the 8th month of gestation than at the 6th month].

    by P Pic, F Dubois, F Pierre, F Barin, A Goudeau

  • Open Access

    Delta Antigenemia Correlated with CD4 Cell Depletion in an Infant with Chronic Hepatitis Delta Virus Infection

    by Philippe Roingeard, Frederic Dubois, Sophie Marchand, Alain Goudeau

    Philippe Roingeard, Frederic Dubois, Sophie Marchand, Alain Goudeau; Delta Antigenemia Correlated with CD4 Cell Depletion in an Infant with Chronic Hepatitis De